An Open-label, Single-arm Study to Evaluate the Efficacy and Safety of RC48-ADC Combined with JS001 in Postoperative Adjuvant Treatment of HER2-positive Upper Tract Urothelial Carcinoma (UTUC)
Latest Information Update: 28 Jan 2025
At a glance
- Drugs Disitamab vedotin (Primary) ; Toripalimab (Primary)
- Indications Urogenital cancer
- Focus Therapeutic Use
- 29 Jun 2023 New trial record